Dupilumab

Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Spekhorst et al., Allergy. 2020 Sep;75(9):2376-2379. doi: 10.1111/all.14324. Epub 2020 May 5. PMID: 32302412; PMCID: PMC7540274.

Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Spekhorst et al., Allergy. 2022 Nov;77(11):3398-3407. doi: 10.1111/all.15439. Epub 2022 Jul 29. PMID: 35837880.

Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics. Großerichter-Wagener et al., 2020 Jan-Dec;12(1):1814661.